Cabaletta Bio (CABA) 8-K: Q3 2025 results press release furnished

Cabaletta Bio, Inc. filed an 8-K announcing it released financial results for the third quarter ended September 30, 2025.

Rhea-AI Filing Summary

Cabaletta Bio, Inc. filed an 8-K announcing it released financial results for the third quarter ended September 30, 2025. The press release detailing these results was furnished as Exhibit 99.1.

The company stated that the information in Item 2.02, including Exhibit 99.1, is being furnished and is not deemed “filed” under Section 18 of the Exchange Act, nor incorporated by reference into Securities Act or Exchange Act filings except as specifically referenced. Cabaletta Bio’s common stock trades on the Nasdaq Global Select Market under the symbol CABA.

8-K Event Classification

Item 2.02 — Results of Operations and Financial Condition

1 item

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Cabaletta Bio (CABA) announce in this 8-K?

The company announced its financial results for the quarter ended September 30, 2025, with details provided in a press release furnished as Exhibit 99.1.

How is the Q3 2025 press release treated legally in this filing?

The information in Item 2.02, including Exhibit 99.1, is being furnished and not deemed “filed” under Section 18 of the Exchange Act.

When was the announcement made?

The press release was issued on November 10, 2025 and furnished with the 8-K on the same date.

Where is Cabaletta Bio’s stock listed and under what ticker?

Cabaletta Bio’s common stock is listed on the Nasdaq Global Select Market under the ticker CABA.

Which exhibit contains the earnings press release?

Exhibit 99.1 contains the press release for the third quarter of 2025.

Who signed the 8-K for Cabaletta Bio?

It was signed by Steven Nichtberger, Chief Executive Officer and President.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/10/2025 - 07:33 AM EST Learn about SEC filing dates

0001759138false00017591382025-11-102025-11-10

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 10, 2025

CABALETTA BIO, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-39103	82-1685768
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
2929 Arch Street Suite 600
Philadelphia, Pennsylvania				19104
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (267) 759-3100

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.00001 per share		CABA		The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On November 10, 2025, Cabaletta Bio, Inc. (the “Company”) announced its financial results for the third quarter ended September 30, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Report on Form 8-K.

The information contained in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

99.1		Press Release issued by the registrant on November 10, 2025, furnished herewith.
104		Cover Page Interactive Data File (embedded within the Inline XBRL Document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		CABALETTA BIO, INC.
Date: November 10, 2025		By:	/s/ Steven Nichtberger
			Steven Nichtberger
			Chief Executive Officer and President (Principal Executive Officer)